Hyloris Pharma expands cardiovascular pipeline by acquiring global rights of Milrinone capsule from the Baker Institute

Hyloris Pharmaceuticals SA, a specialty biopharma company, has acquired the global rights from the Baker Heart and Diabetes Institute (the Baker Institute), Melbourne, Australia, to CRD─102 (and related intellectual property)